TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02934477

Intervention type: OTHER
Intervention: Hematopoietic Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
Study: NCT00845871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox:
Description: Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
Study: NCT00749801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nattokinase
Description: 2 capsules in the morning and before bed-time daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nattokinase
Description: 2 capsules in the morning and before bed-time daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nattokinase
Description: 2 capsules in the morning and before bed-time daily
Study: NCT04959149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirTraq videolaryngoscope
Description: intubation of morbidly obese patient using Airtraq videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirTraq videolaryngoscope
Description: intubation of morbidly obese patient using Airtraq videolaryngoscope
Study: NCT02862041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echogenic needle - Pajunk sonoplex echogenic needle
Description: Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non Echogenic needle - Stimuplex Braun Nonechogenic needle
Description: Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
Study: NCT01664936

Intervention type: RADIATION
Intervention: Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I
Description: We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
Study: NCT02559609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for alcohol abstinence
Description: Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for alcohol abstinence
Description: Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for completing job related activities
Description: Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management for completing job related activities
Description: Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Job relelated activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job relelated activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job relelated activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Job relelated activity contracting
Description: Participants will complete job-related activity contracts each week with the goal of obtaining employment.
Study: NCT04376294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy(ESWT)
Description: Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training of the calf muscle:
Description: The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric training of the calf muscle:
Description: The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastrocnemius, soleus, and hamstring stretch
Description: Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastrocnemius, soleus, and hamstring stretch
Description: Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
Study: NCT04756011

Intervention type: OTHER
Intervention: Health related quality of life
Description: Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL

Intervention type: OTHER
Intervention: Health related quality of life
Description: Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
Study: NCT02718534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroke rehabilitation
Description: Physical rehabilitation exercise between 24 and 48 hours and after 48 hours

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stroke rehabilitation
Description: Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
Study: NCT03112200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subchondroplasty with Arthroscopy
Description: The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopy Alone
Description: An endoscopic examination, therapy and surgery of the knee joint.
Study: NCT00354133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinetra and Soletra (neurostimulator, Medtronic)
Description: Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Patients in this arm get best medical treatment only
Study: NCT03240341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Activation Measure Questionnaire
Description: Measure the level of patient engagement in cancer care pathway
Study: NCT01209481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional education group action
Description: The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
Study: NCT03313115

Intervention type: BEHAVIORAL
Intervention: Sleep/Wake Protocol
Description: Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet
Study: NCT03161119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided embryotransfer with Cook K-Jets-551910-S
Description: On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)
Description: On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias.
Study: NCT02181972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gingko biloba

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04370743

Intervention type: OTHER
Intervention: No intervention
Study: NCT03746977

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Protein supplementation 1.2 or 1.5 g/kg body mass/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Protein supplementation 1.2 or 1.5 g/kg body mass/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Protein supplementation 1.2 or 1.5 g/kg body mass/d

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Walking with a volume corresponding to 250 kcal/d

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Walking with a volume corresponding to 250 kcal/d

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS application
Description: WB-EMS application 1.5x 20 min/week
Study: NCT03050437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin is added to Pem/cis arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pem is applied to both arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pem is applied to both arms
Study: NCT04321993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib (janus kinase inhibitor)
Description: Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (antiviral) + barictinib (janus kinase inhibitor)
Description: Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (antiviral)
Description: Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (interleukin 6 inhibitor)
Description: Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
Study: NCT02150265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART manual cognitive behavioral therapy
Study: NCT04069429

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computerized Tomography scan
Description: imaging scan from a person's eyes to their thighs

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography scans
Description: imaging scan taken during, and after, the administration of the radioactive agent

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography scans
Description: imaging scan taken during, and after, the administration of the radioactive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M
Description: subjects are administered radioactive heparin as part of study participation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99M
Description: subjects are administered radioactive heparin as part of study participation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Planar Images
Description: 2 dimensional imaging - whole body planar scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Planar Images
Description: 2 dimensional imaging - whole body planar scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: esophagogastroduodenoscopy with tissue biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: esophagogastroduodenoscopy with tissue biopsies
Study: NCT03974100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2411
Description: 60 mg /mL subcutaneous injection every 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia (EU-authorized Prolia®)
Description: 60 mg /mL subcutaneous injection every 6 months
Study: NCT04522583

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of Myocardial Ischemia
Description: Discharge diagnosis of myocardial ischemia
Study: NCT06192719

Intervention type: OTHER
Intervention: None, observational study.
Description: Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.

Intervention type: OTHER
Intervention: None, observational study.
Description: Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
Study: NCT01793298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: Ascending doses of ASM-024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: Ascending doses of ASM-024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: Ascending doses of ASM-024
Study: NCT00114543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Phototherapy 501-750g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Phototherapy 751-1000g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Phototherapy 501-750g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Phototherapy 751-1000g
Description: Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
Study: NCT00920699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
Study: NCT02564718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
Study: NCT00953862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
Study: NCT01723007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplement
Description: The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
Study: NCT01222702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin, provided as capsules (125 mg) for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-matching cadazolid
Description: Placebo of cadazolid powder for oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching vancomycin
Description: Placebo of vancomycin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching vancomycin
Description: Placebo of vancomycin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching vancomycin
Description: Placebo of vancomycin capsules
Study: NCT02287883

Intervention type: OTHER
Intervention: Observational: Patient Activation and Engagement (PAE)
Description: Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.

Intervention type: OTHER
Intervention: Observational: Patient Activation and Engagement (PAE)
Description: Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
Study: NCT01744756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: One subconjunctival aplication of Bevacizumabe 0,5ml
Study: NCT00614588

Intervention type: DEVICE
Intervention: Body temperature thermometers
Description: Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
Study: NCT01335321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan GF-20 alone
Description: A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)